Nesiritide

• Description:

  Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury[1][2][3][4][5][6][7].

• Product Name Alternative:

  Brain Natriuretic Peptide-32 human; BNP-32

• UNSPSC:

  12352209

• Target:

  Calcium Channel; Natriuretic Peptide Receptor (NPR)

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Nesiritide.html

• Purity:

  99.75

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (N[C@H] (C (NCC (N[C@H] (C (N[C@H] (C (N[C@H] (C (N[C@H] (C (N[C@H] (C (N[C@@] (C (N[C@H] (C (N[C@H] (C (N[C@H] (C (N[C@H] (C (NCC (N[C@H] (C (NCC (N[C@@H] (CSSC1) C (N[C@@H] (CCCCN) C (N[C@@H] (C (C) C) C (N[C@@H] (CC (C) C) C (N[C@@H] (CCCNC (N) =N) C (N[C@@H] (CCCNC (N) =N) C (N[C@H] (C (O) =O) CC2=CN=CN2) =O) =O) =O) =O) =O) =O) =O) =O) CC (C) C) =O) =O) CO) =O) CO) =O) CO) =O) CO) =O) ([H]) [C@@H] (C) CC) =O) CCCNC (N) =N) =O) CC (O) =O) =O) CCSC) =O) CCCCN) =O) CCCNC (N) =N) =O) =O) CC3=CC=CC=C3) [C@H]1NC (CNC ([C@H] (CO) NC (CNC ([C@H] (CCC (N) =O) NC ([C@H] (C (C) C) NC ([C@H] (CCSC) NC ([C@H] (CCCCN) NC ([C@H]4N (CCC4) C ([C@@H] (N) CO) =O) =O) =O) =O) =O) =O) =O) =O) =O

• Molecular Formula:

  C143H244N50O42S4

• Molecular Weight:

  3464.04

• References & Citations:

  [1]Koller KJ, et al. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992 Oct;86 (4) :1081-8.|[2]Sodi R, et al. B-type natriuretic peptide (BNP) attenuates the L-type calcium current and regulates ventricular myocyte function. Regul Pept. 2008 Nov 29;151 (1-3) :95-105.|[3]Lazar HL, et al. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg. 2009 Sep-Oct;24 (5) :600-5.|[4]Liu S Q, et al. Nesiritide protects endothelial function after balloon-induced trauma in the iliac artery in rabbits. Brazilian Journal of Pharmaceutical Sciences, 2020, 56: e18430. |[5]Liu SQ, et al. Treatment with nesiritide, a recombinant B-type natriuretic Peptide, reduces vascular remodeling following balloon-induced endothelial injuries in rabbits. Tohoku J Exp Med. 2010 Nov;222 (3) :219-23.|[6]Liu SQ, et al. Recombinant B-type natriuretic peptide nesiritide attenuates vascular remodelling by reducing plasma aldosterone in rabbits. Heart Lung Circ. 2012 Sep;21 (9) :551-5.|[7]Hobbs RE, et al. Therapeutic potential of nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure. Expert Opin Investig Drugs. 1999 Jul;8 (7) :1063-72.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Peptides

• Clinical Information:

  Launched

• CAS Number:

  124584-08-3